We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$18.7M
Cap. Flow
+$14.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
6.4%
Holding
553
New
113
Increased
199
Reduced
149
Closed
92

Top Buys

Rank Stock Value
1
EXPD icon
Expeditors International
EXPD
+$2.17M
2
INCY icon
Incyte
INCY
+$2.09M
3
WAT icon
Waters Corp
WAT
+$2.03M
4
AMAT icon
Applied Materials
AMAT
+$2.01M
5
LVS icon
Las Vegas Sands
LVS
+$2.01M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.5M
2
EA
Electronic Arts
EA
+$2.43M
3
FOXA icon
Fox Class A
FOXA
+$2.05M
4
MS icon
Morgan Stanley
MS
+$2.04M
5
ATO icon
Atmos Energy
ATO
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 26.73%
2 Financials 22.73%
3 Technology 18.16%
4 Industrials 8.89%
5 Consumer Discretionary 7.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
176
PTC Therapeutics
PTCT
$6.12B
$686K 0.19%
9,033
+316
+4% +$23K
BNTX icon
177
BioNTech
BNTX
$23.5B
$686K 0.19%
7,207
+2,971
+70% +$299K
VRTX icon
178
Vertex Pharmaceuticals
VRTX
$126B
$685K 0.19%
1,511
+545
+56% +$235K
MRNA icon
179
Moderna
MRNA
$23.6B
$684K 0.19%
23,197
+6,949
+43% +$189K
ARQT icon
180
Arcutis Biotherapeutics
ARQT
$3.18B
$684K 0.19%
23,549
+15,120
+179% +$387K
SRPT icon
181
Sarepta Therapeutics
SRPT
$1.77B
$683K 0.19%
31,741
+19,830
+166% +$418K
ALNY icon
182
Alnylam Pharmaceuticals
ALNY
$29.3B
$683K 0.19%
1,717
+258
+18% +$114K
AGIO icon
183
Agios Pharmaceuticals
AGIO
$1.93B
$682K 0.19%
25,060
+12,179
+95% +$427K
LGND icon
184
Ligand Pharmaceuticals
LGND
$6.36B
$682K 0.19%
3,605
-278
-7% -$53.4K
APLS
185
DELISTED
Apellis Pharmaceuticals
APLS
$680K 0.18%
27,086
+4,013
+17% +$94.2K
ZLAB icon
186
Zai Lab
ZLAB
$2.62B
$678K 0.18%
38,457
+28,129
+272% +$659K
KNSA icon
187
Kiniksa Pharmaceuticals
KNSA
$5.93B
$678K 0.18%
16,432
+406
+3% +$16.3K
JFR icon
188
Nuveen Floating Rate Income Fund
JFR
$1.25B
$677K 0.18%
86,463
-23,248
-21% -$183K
UTHR icon
189
United Therapeutics
UTHR
$23.1B
$673K 0.18%
1,382
-171
-11% -$79.6K
ACAD icon
190
Acadia Pharmaceuticals
ACAD
$5.03B
$672K 0.18%
25,170
+4,729
+23% +$113K
ROIV icon
191
Roivant Sciences
ROIV
$26.2B
$671K 0.18%
30,922
-7,822
-20% -$154K
IONS icon
192
Ionis Pharmaceuticals
IONS
$9.4B
$669K 0.18%
8,454
-4,022
-32% -$303K
JQC icon
193
Nuveen Credit Strategies Income Fund
JQC
$711M
$667K 0.18%
132,878
-27,736
-17% -$141K
LEGN icon
194
Legend Biotech
LEGN
$4.01B
$666K 0.18%
30,617
+18,895
+161% +$541K
FCT
195
First Trust Senior Floating Rate Income Fund II
FCT
$251M
$664K 0.18%
65,895
-18,398
-22% -$179K
GERN icon
196
Geron
GERN
$949M
$663K 0.18%
502,509
+217,641
+76% +$273K
BCSF icon
197
Bain Capital Specialty
BCSF
$850M
$663K 0.18%
47,637
-8,234
-15% -$115K
ASND icon
198
Ascendis Pharma A/S
ASND
$16.8B
$661K 0.18%
3,100
+500
+19% +$103K
BBDC icon
199
Barings BDC
BBDC
$965M
$657K 0.18%
71,617
-14,449
-17% -$128K
ESPR
200
DELISTED
Esperion Therapeutics
ESPR
$657K 0.18%
+177,508
New +$574K
6 7
8
9 10

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q4 2025 Portfolio in Review

As of Q4 2025, Virtus Investment Advisers held 553 positions worth $368M, up 5.3% from $349M the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.

Virtus Investment Advisers deployed $14.9M of net new capital in Q4 2025, opening 113 new positions and adding to 199 existing holdings. Its largest new stake was Expeditors International: 15,974 shares worth $2.38M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 17% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was VICI Properties, an estimated $1.66M trimmed.

  • Virtus Investment Advisers's largest Q4 2025 buy was Expeditors International: 15,974 shares worth $2.38M.
  • Virtus Investment Advisers added most to Incyte in Q4 2025, an estimated $2.09M increase.
  • Virtus Investment Advisers's biggest Q4 2025 reduction was VICI Properties, cutting an estimated $1.66M.
  • Virtus Investment Advisers fully exited Tesla in Q4 2025, selling an estimated $2.5M.
  • Virtus Investment Advisers's ten largest holdings make up 6.4% of its $368M portfolio in Q4 2025.
  • Virtus Investment Advisers opened 113 new positions and closed 92 in Q4 2025.
  • Virtus Investment Advisers's portfolio value rose 5.3% quarter-over-quarter to $368M.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.